International Hepatology

Background and Objective Hepatocellular carcinoma (HCC) is among the most common malignancies globally, with a high recurrence rate after resection, especially in patients with risk factors like large tumor size,…

Editor’s Note: On the morning of March 28, the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025) officially opened. During the keynote session, APASL 2025 Scientific Committee Chair, Academician Jiahong Dong of Beijing Tsinghua Changgung Hospital, delivered a keynote speech titled “Precision Surgical Treatment of Liver Diseases” and participated in an in-depth interview with International Hepatology. In his address, Academician Dong presented IDEAL—China’s first multimodal intelligent system for precision surgical decision-making in liver diseases. He explained how IDEAL enhances the accuracy, safety, and minimally invasive nature of liver surgery, offering patients greater health benefits. Dong also emphasized the transformative role of digital technologies in surgical care, predicting their impact across clinical evaluation, surgical planning, decision-making, and data management, thus accelerating innovation in the field of hepatobiliary surgery.

In a recent editorial published in the Journal of Hepatology (April 2025), Prof. Heiner Wedemeyer (Hannover Medical School) a leading voice in hepatology joined Niklas Luhmann in reflecting on more…

In a recent editorial published in the Journal of Hepatology (March 24, 2025), Professors Debbie Shawcross and Vishal C. Patel spotlight the THEMATIC trial—a phase II RCT investigating the safety…

Highlights of the Congress The 34th Annual Meeting of the Asia-Pacific Association for the Study of the Liver (APASL) concluded successfully in Beijing on March 30, 2025. Under the theme…

We’re honored to present an exclusive dialogue featuring Professor Julien Calderaro, President of the 2025 EASL Liver Cancer Summit, and Professor Jian Zhou from Zhongshan Hospital, Fudan University and the President of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE).

Liver diseases remain a global challenge with complex diagnostic and therapeutic hurdles. Addressing these requires not only pooling the expertise of global specialists but also integrating valuable experiences from both Eastern and Western medical practices.

Dr. Lai Wei: Currently, two-thirds of global viral hepatitis cases are concentrated in Asia, with about half occurring in China. The World Health Organization (WHO) aims to reduce new viral hepatitis infections by 90% and related mortality by 65% by 2030. Thus, contributions from the Asia-Pacific region are pivotal in achieving these elimination goals.

Liver cancer remains one of the deadliest malignancies worldwide, with China carrying a significant burden of cases. Understanding the unique epidemiology, molecular characteristics, and treatment strategies across different regions is crucial for advancing patient outcomes. In an exclusive cross-border dialogue, Professor Qin Shukui of Nanjing Tianyin Mountain Hospital, China, and Professor Pablo Sarobe of the University of Navarra Medical School, Spain, share their insights into the latest breakthroughs in liver cancer treatment. They discuss the evolving role of immunotherapy, targeted therapy, and the importance of global collaboration in shaping the future of liver cancer care. Watch the full conversation to gain expert perspectives on emerging treatment strategies, biomarker-driven approaches, and the future of liver cancer therapy.

Editorial Note: Transjugular intrahepatic portosystemic shunt (TIPS) is an effective intervention for managing complications of portal hypertension in cirrhosis, such as refractory ascites or secondary prevention of esophageal and gastric…